Canadian Sec - Delayed Quote CAD
METheraHld (METX.CN)
9.50
+0.50
+(5.56%)
At close: May 2 at 2:40:10 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Salim Zulifkar Dhanji Ph.D. | CEO & Director | 50k | -- | -- |
| Mr. Quinn Martin C.A., CPA | Chief Financial Officer | 37.5k | -- | 1983 |
| Mr. Jamil Kassam | Corporate Secretary | -- | -- | -- |
| Mr. Karim F. Lalji M.S., MS, SM | Chief Business Officer | -- | -- | -- |
METheraHld
- Sector:
- Healthcare
- Industry: Biotechnology
Description
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
Corporate Governance
METheraHld’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 11, 2025 at 10:59 AM UTC
METheraHld Earnings Date